Plus Therapeutics (NASDAQ:CNSY) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Plus Therapeutics (NASDAQ:CNSY – Free Report) from a strong sell rating to a hold rating in a research note published on Tuesday morning,Zacks reports.

Separately, Weiss Ratings assumed coverage on shares of Plus Therapeutics in a research report on Tuesday, August 4th. They issued a “sell (e+)” rating for the company. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

Get Plus Therapeutics alerts:

Read Our Latest Stock Analysis on Plus Therapeutics

Plus Therapeutics Trading Up 8.5%

CNSY opened at $2.94 on Tuesday. Plus Therapeutics has a 1 year low of $2.62 and a 1 year high of $23.42. The firm has a market cap of $22.31 million, a price-to-earnings ratio of -0.88 and a beta of 1.39.

Plus Therapeutics (NASDAQ:CNSY – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.35). Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. On average, analysts expect that Plus Therapeutics will post -3.76 EPS for the current fiscal year.

About Plus Therapeutics

(Get Free Report)

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.

Read More

• Five stocks we like better than Plus Therapeutics
• Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
• J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
• Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
• GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test

Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.